Welcome to our dedicated page for Inspire Medical Systems SEC filings (Ticker: INSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Inspire Medical Systems's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Inspire Medical Systems's regulatory disclosures and financial reporting.
Inspire Medical Systems reported Q3 2025 growth with lower profitability. Revenue rose to $224.5 million from $203.2 million as U.S. sales remained the core driver. Gross profit reached $192.7 million, but higher operating costs, including advertising and SG&A, reduced operating income to $9.6 million from $14.3 million.
Net income was $9.9 million versus $18.5 million a year ago, with diluted EPS of $0.34 versus $0.60. For the first nine months, revenue was $642.9 million and net income was $9.3 million. Cash and cash equivalents were $112.8 million, with $209.7 million in short-term investments. Inventories increased to $141.8 million from $80.1 million, reflecting production and demand planning.
The company continued capital returns: it completed an accelerated share repurchase totaling 409,043 shares at an average price of $190.29, repurchased 442,649 shares for $75.0 million earlier in 2025, and bought 552,423 shares for $50.0 million under a new $200.0 million program, leaving $150.0 million authorized. Shares outstanding were 29,053,367 at September 30, 2025.
Inspire Medical Systems reported that it issued a press release announcing financial results for the quarter ended September 30, 2025, and furnished an investor presentation for upcoming meetings with investors and analysts.
The materials are provided as Exhibits 99.1 (press release) and 99.2 (presentation). The company noted these items are furnished, not filed, under the Exchange Act. The investor presentation is also available on the company’s Investor Relations website.
BlackRock, Inc. filed an amended Schedule 13G reporting a passive ownership stake in Inspire Medical Systems (INSP). As of September 30, 2025, BlackRock beneficially owned 3,353,407 shares of INSP, representing 11.3% of the common stock. The filing lists sole voting power over 3,283,122 shares and sole dispositive power over 3,353,407 shares, with no shared voting or dispositive power.
BlackRock certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing notes that iShares Core S&P Small-Cap ETF has an interest in INSP common stock that is more than five percent of the total outstanding shares.
Inspire Medical Systems (INSP) reported an insider transaction by a director. On 10/14/2025, the director acquired 229 shares of common stock at $78.84 per share, received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy. After this transaction, the director beneficially owns 3,986 shares, held directly.
Inspire Medical Systems (INSP) director Casey M. Tansey reported an equity award. On 10/14/2025, Tansey acquired 221 shares of common stock at $78.84 per share, received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy.
Following this transaction, Tansey beneficially owned 22,235 shares directly. Additional indirect holdings reported include 500 shares held by The Kimberly Tansey Irrevocable Trust and 500 shares held by The Kylie Tansey Irrevocable Trust.
Inspire Medical Systems (INSP) director Gary L. Ellis reported acquiring 372 shares of common stock on October 14, 2025. The shares were received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, at a reported price of $78.84 per share.
Following this transaction, Ellis beneficially owns 6,454 shares, held directly. This filing reflects routine director compensation settled in stock rather than cash.
Inspire Medical Systems (INSP) reported an insider equity award. Director Shelley G. Broader acquired 245 shares of common stock on 10/14/2025 at $78.84 per share. The shares were received in lieu of cash fees under the company's Non-Employee Director Compensation Policy.
After this transaction, Broader’s beneficial ownership stands at 4,367 shares, held directly.
Inspire Medical Systems, Inc. filed a current report describing upcoming investor and analyst meetings in October 2025. The company is using a prepared slide presentation for these meetings, which is furnished as Exhibit 99.2 and made available on its investor relations website.
The filing also lists a related press release as Exhibit 99.1. The company clarifies that the presentation materials and related disclosure are furnished, not filed, so they are not subject to certain Exchange Act liability provisions or automatically incorporated into other securities law filings.
FMR LLC and Abigail P. Johnson filed Amendment No. 4 to a Schedule 13G reporting ownership of common stock of Inspire Medical Systems, Inc. The filing shows an aggregate beneficial ownership of 741,312.10 shares, representing 2.5% of the outstanding common stock. FMR LLC reports sole voting power of 739,599 shares and sole dispositive power of 741,312.10 shares; Abigail P. Johnson reports sole dispositive power of 741,312.10 shares and no voting power. The filers certify the shares are held in the ordinary course of business and not for the purpose of changing control. The filing includes referenced exhibits and powers of attorney.
Citadel and related entities reported ownership stakes in Inspire Medical Systems (INSP). The joint Schedule 13G shows Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC each may be deemed to beneficially own 1,379,861 shares representing 4.7% of outstanding common stock. Citadel Securities LLC reported 114,245 shares (0.4%), and Citadel Securities Group LP and Citadel Securities GP LLC each reported 333,181 shares (1.1%). Mr. Kenneth Griffin is reported with shared beneficial ownership of 1,713,042 shares (5.8%). The filing states holdings are as of the market open on 10/06/2025 and uses a share base of 29,574,316 shares for percentage calculations.